Dökmetaş H S, Colak R, Keleştimur F, Selçuklu A, Unlühizarci K, Bayram F
Department of Endocrinology, Erciyes University, Medical School, Kayseri, Turkey.
J Clin Endocrinol Metab. 2000 Oct;85(10):3713-9. doi: 10.1210/jcem.85.10.6879.
The short ACTH stimulation test is an easy, reliable, and extensively used test in the assessment of the hypothalamo-pituitary-adrenal (HPA) axis. However, its use immediately after pituitary surgery is a matter of debate. The insulin tolerance test (ITT) is the gold standard in the evaluation of the HPA axis, but it is not always without side effects and may be unpleasant early after pituitary surgery. Our aim was to investigate the value of the 1-microg ACTH test in the assessment of the HPA axis early after pituitary surgery. We also aimed to determine the value of the 1-microg and 250-microg ACTH tests and the ITT in the estimation of HPA axis status after 3 months postoperatively. Nineteen patients subjected to pituitary tumor surgery were included in the study, and the ITT and the 1-microg and 250-microg ACTH tests were performed between the 4th and 11th days of surgery. The tests were repeated at the first month in 3 patients with subnormal peak cortisol responses (454, 125, and 301 nmol/L) and in 18 patients at the third month postoperatively. ACTH stimulation tests were performed by using 1 microg and 250 microg ACTH iv as a bolus injection, and blood samples were drawn at 0, 30, and 60 min for measurement of serum cortisol levels. The ITT was performed by using iv regular insulin, and serum glucose and cortisol levels were measured. The 1-microg and 250-microg ACTH stimulation tests and the ITT were performed consecutively. At least 48 h were allowed between each test. A peak serum cortisol level of 550 nmol/L or greater was considered as a normal response for both the ITT and the ACTH tests. The serum cortisol level was measured by RIA using commercial kits. Serum glucose was determined by glucose oxidase method. There were correlations between the peak cortisol response to the ITT and the 1-microg ACTH test (r = 0.39, P < 0.05) in the early postoperative period. No correlation was found between the ITT and the 250-microg ACTH test responses. In the early postoperative period, two patients showed normal cortisol responses (> or =550 nmol/L) to the 1-microg ACTH test and five patients showed normal cortisol responses to the 250-microg ACTH test among the six patients with subnormal cortisol responses to the ITT. Three patients with subnormal cortisol responses to ITT and baseline cortisol values less than 240 nmol/L showed normal HPA axis at the end of the first month. In the late postoperative period, at the third month, all the patients showed normal HPA axis. In the early postoperative period of pituitary surgery, the 1-microg ACTH test results are more concordant than the 250-microg ACTH test in comparison with the ITT. Our results also indicate that HPA axis dysfunction shown by ACTH stimulation tests and the ITT in early postoperative period may be normalized 1-3 months after surgery. For this reason, we think that dynamic tests including the ITT may not be useful early after pituitary surgery.
短程促肾上腺皮质激素(ACTH)刺激试验是评估下丘脑 - 垂体 - 肾上腺(HPA)轴的一种简便、可靠且广泛应用的试验。然而,垂体手术后立即使用该试验存在争议。胰岛素耐量试验(ITT)是评估HPA轴的金标准,但它并非总是没有副作用,且在垂体手术后早期可能会令人不适。我们的目的是研究1微克ACTH试验在垂体手术后早期评估HPA轴中的价值。我们还旨在确定1微克和250微克ACTH试验以及ITT在术后3个月评估HPA轴状态中的价值。19例接受垂体肿瘤手术的患者纳入研究,在手术第4至11天进行ITT以及1微克和250微克ACTH试验。3例皮质醇峰值反应低于正常水平(454、125和301 nmol/L)的患者在术后第1个月重复进行试验,18例患者在术后第3个月重复试验。通过静脉推注1微克和250微克ACTH进行ACTH刺激试验,并在0、30和60分钟采集血样以测量血清皮质醇水平。通过静脉注射正规胰岛素进行ITT,并测量血清葡萄糖和皮质醇水平。1微克和250微克ACTH刺激试验以及ITT连续进行。每次试验之间至少间隔48小时。ITT和ACTH试验的血清皮质醇峰值水平≥550 nmol/L被视为正常反应。使用商业试剂盒通过放射免疫分析法(RIA)测量血清皮质醇水平。通过葡萄糖氧化酶法测定血清葡萄糖。术后早期,ITT与1微克ACTH试验的皮质醇峰值反应之间存在相关性(r = 0.39,P < 0.05)。未发现ITT与250微克ACTH试验反应之间存在相关性。术后早期,在ITT皮质醇反应低于正常水平的6例患者中,2例对1微克ACTH试验显示正常皮质醇反应(≥550 nmol/L),5例对250微克ACTH试验显示正常皮质醇反应。3例ITT皮质醇反应低于正常水平且基线皮质醇值低于240 nmol/L的患者在第1个月末显示HPA轴正常。术后晚期,即第3个月时,所有患者HPA轴均正常。在垂体手术术后早期,与ITT相比,1微克ACTH试验结果比250微克ACTH试验更一致。我们的结果还表明,术后早期ACTH刺激试验和ITT显示的HPA轴功能障碍可能在术后1 - 3个月恢复正常。因此,我们认为包括ITT在内的动态试验在垂体手术后早期可能无用。